Anti-CA19-9/Sialyl Lewis A (sLeA) Antibody

CA19-9/Sialyl Lewis A (sLeA)

Shipped on ice packs

120-400 kDa

24 months from date of receipt

Human

CA19-9/ Sialyl Lewis a (sialyted lacto-N-fucopentose) (α-NeuNAc-(2→3)-β-D-Gal-(1→3)-(α-L-Fuc-[1→4])-D-GlcNAc, 3′-SLea) corresponds to blood group antigens. In normal tissue Sialyl Lewis a is present in ductal epithelium of the breast, kidney and salivary glands. This antigen is expressed is increased in all gastrointestinal carcinomas (stomach, intestine and pancreas) (1) While it is not useful to diagnose particular forms of cancer, specifically pancreatic cancer, it may be useful to monitor the results of treatment and to determine whether the disease may be recurring (3) Other causes for elevated CA19-9 levels include Mirizzi’s syndrome and other hepatobiliary diseases (2) In patients that do not have the Lewis antigen blood type (about 5% of the population), CA19-9 is not elevated in pancreatic cancer even with large tumors because they have a deficiency of fucosyltransferase that is needed to produce CA19-9 (1).

No cross-reactivity reported

Purified by Protein A Chromatography

Produced by in vitro bioreactor culture of hybridoma line followed by Protein A affinity chromatography. Purified mAbs are >90% specific antibody.

WB

1:200

These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.

Carbohydrate moiety